Oxford Biomedica PLC (LSE: OXB), a FTSE 250 cell and gene therapy contract development and manufacturing organisation, has notified the market that 430,825 new ordinary shares have been admitted to trading on the London Stock Exchange's Main Market. The shares were allotted under the company's Long Term Incentive Plan and Deferred Bonus Plan, covering the period from 5 October 2026 to 12 November 2026. The admission brings OXB's total shares admitted to trading to 121,480,983 ordinary shares of 50 pence each, and the company has confirmed the new shares are fully fungible with existing shares already listed.

Key Points

  • Oxford Biomedica PLC (LSE: OXB), FTSE 250 and FTSE4Good constituent, headquartered in Oxford, UK
  • 430,825 new ordinary shares admitted to trading under the OXB Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP)
  • Total shares now admitted to trading: 121,480,983 ordinary shares of 50p each (ISIN: GB00BDFBVT43); admission covers 5 October–12 November 2026
  • Investors may watch for further employee share scheme allotments and any update on OXB's commercial CDMO pipeline

OXB Allots Shares Under Long Term Incentive Plan and Deferred Bonus Plan

The admission, disclosed in accordance with the Financial Conduct Authority's Prospectus Rules (PRM sourcebook 1.6.4R), relates solely to shares allotted through OXB's established employee incentive arrangements. The Long Term Incentive Plan and Deferred Bonus Plan are standard mechanisms used by listed companies to align employee and executive interests with long-term shareholder value. The notification confirms the new ordinary shares, each carrying a nominal value of 50 pence, are fungible with the existing share capital, meaning they carry identical rights and are interchangeable with previously listed shares on the London Stock Exchange's Main Market.

Oxford Biomedica's Role as a Global Cell and Gene Therapy CDMO

Oxford Biomedica operates as a quality and innovation-led contract development and manufacturing organisation specialising in viral vectors, which the company describes as the driving force behind the majority of cell and gene therapies. With over 30 years of experience, OXB collaborates with pharmaceutical and biotechnology companies globally, providing expertise across lentiviral, AAV, adenoviral, MVA and other viral vector platforms. Its proprietary technologies include the fourth-generation TetraVecta™ lentiviral vector system and a dual-plasmid system for AAV production. The company's capabilities span early-stage development through to commercialisation, supported by regulatory and analytical expertise.

OXB's International Manufacturing Footprint Underpins CDMO Capacity

OXB maintains development and manufacturing facilities across multiple geographies, including sites in Oxfordshire, and in Lyon and Strasbourg in France, as well as Bedford, Massachusetts and Durham, North Carolina in the United States. This international infrastructure supports OXB's ability to serve global biopharmaceutical clients at scale. The company's inclusion in both the FTSE 250 and FTSE4Good indices reflects its market capitalisation standing and its commitment to environmental, social and governance criteria, factors that institutional investors in the life sciences CDMO sector often consider when assessing holdings.